Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose alkylating chemotherapy in oligo-metastatic breast cancer
NCT01646034Phase 3Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2014
- Primary completion
- Jan 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of carboplatin, thiotepa, cyclophosphamide in breast cancer, sponsored by Netherlands Cancer Institute. Started Sep 2014; status: active, not recruiting.
02
Drugs
carboplatinthiotepacyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01646034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01646034.